Emerging Infections

As concern about Zika virus mounts, the Food and Drug Administration on Feb. 26 authorized use of an investigational test from the Centers for Disease Control and Prevention to detect antibodies in sera and cerebrospinal fluid.

Known as the Zika Immunoglobulin M Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA), the test is available under an FDA Emergency Use Authorization to labs certified by CDC for high-complexity tests.

If infection is suspected, “the Zika MAC-ELISA may be ordered. Please contact your state or local health department to facilitate testing,” FDA said in a fact sheet for health care providers.

“At this time, there are no FDA approved/cleared tests available that can detect Zika virus in clinical specimens in the United States. Therefore, CDC has developed this test to detect evidence of Zika virus infections.” Positive and inconclusive results must be confirmed by CDC or authorized laboratories, the FDA noted.

Testing is appropriate in patients with signs and symptoms of Zika virus infection who recently traveled to areas with active transmissions. Anti-Zika IgM can usually be detected after about 4 days of symptoms, and remains detectable for about 3 months.

Most who are infected with the Zika virus don’t know they have it. For others, symptoms set in after a few days, tend to be mild, last about a week, and can include fever, rash, joint pain, and conjunctivitis. The virus has, however, been associated in Brazil with Guillain-Barre syndrome and microcephaly, although detection in pregnant women does not necessarily mean the fetus has been harmed.

So far, there have been more than 90 confirmed cases of Zika infection in the United States, most, but not all, in people who had recently traveled to endemic areas.

The FDA did not report sensitivity and specificity figures, but it’s clear from what it did say that reliability is an issue. Closely-related flavivirus infections, such as dengue fever, can trigger false positives, and in patients vaccinated against yellow fever or Japanese encephalitis, cross-reactive antibodies can also “make it difficult to identify which flavivirus is causing the patient’s current illness,” the fact sheet noted.

False negatives should be considered when “recent exposures or clinical presentation are consistent with Zika virus infection and diagnostic tests for other causes of illness are negative. Conversely, a negative result in an asymptomatic patient with a lower likelihood of exposure (e.g., a short term traveler to an affected area) may suggest the patient is not infected,” the FDA noted.

Zika MAC-ELISA labeling, fact sheets for patients, and other materials are available on the FDA’s Emergency Use Authorizations webpage. The CDC has a Zika virus site for health care providers, as well.

[email protected]

As concern about Zika virus mounts, the Food and Drug Administration on Feb. 26 authorized use of an investigational test from the Centers for Disease Control and Prevention to detect antibodies in sera and cerebrospinal fluid.

Known as the Zika Immunoglobulin M Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA), the test is available under an FDA Emergency Use Authorization to labs certified by CDC for high-complexity tests.

If infection is suspected, “the Zika MAC-ELISA may be ordered. Please contact your state or local health department to facilitate testing,” FDA said in a fact sheet for health care providers.

“At this time, there are no FDA approved/cleared tests available that can detect Zika virus in clinical specimens in the United States. Therefore, CDC has developed this test to detect evidence of Zika virus infections.” Positive and inconclusive results must be confirmed by CDC or authorized laboratories, the FDA noted.

Testing is appropriate in patients with signs and symptoms of Zika virus infection who recently traveled to areas with active transmissions. Anti-Zika IgM can usually be detected after about 4 days of symptoms, and remains detectable for about 3 months.

Most who are infected with the Zika virus don’t know they have it. For others, symptoms set in after a few days, tend to be mild, last about a week, and can include fever, rash, joint pain, and conjunctivitis. The virus has, however, been associated in Brazil with Guillain-Barre syndrome and microcephaly, although detection in pregnant women does not necessarily mean the fetus has been harmed.

So far, there have been more than 90 confirmed cases of Zika infection in the United States, most, but not all, in people who had recently traveled to endemic areas.

The FDA did not report sensitivity and specificity figures, but it’s clear from what it did say that reliability is an issue. Closely-related flavivirus infections, such as dengue fever, can trigger false positives, and in patients vaccinated against yellow fever or Japanese encephalitis, cross-reactive antibodies can also “make it difficult to identify which flavivirus is causing the patient’s current illness,” the fact sheet noted.

False negatives should be considered when “recent exposures or clinical presentation are consistent with Zika virus infection and diagnostic tests for other causes of illness are negative. Conversely, a negative result in an asymptomatic patient with a lower likelihood of exposure (e.g., a short term traveler to an affected area) may suggest the patient is not infected,” the FDA noted.

Zika MAC-ELISA labeling, fact sheets for patients, and other materials are available on the FDA’s Emergency Use Authorizations webpage. The CDC has a Zika virus site for health care providers, as well.

[email protected]

As concern about Zika virus mounts, the Food and Drug Administration on Feb. 26 authorized use of an investigational test from the Centers for Disease Control and Prevention to detect antibodies in sera and cerebrospinal fluid.

Known as the Zika Immunoglobulin M Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA), the test is available under an FDA Emergency Use Authorization to labs certified by CDC for high-complexity tests.

If infection is suspected, “the Zika MAC-ELISA may be ordered. Please contact your state or local health department to facilitate testing,” FDA said in a fact sheet for health care providers.

“At this time, there are no FDA approved/cleared tests available that can detect Zika virus in clinical specimens in the United States. Therefore, CDC has developed this test to detect evidence of Zika virus infections.” Positive and inconclusive results must be confirmed by CDC or authorized laboratories, the FDA noted.

Testing is appropriate in patients with signs and symptoms of Zika virus infection who recently traveled to areas with active transmissions. Anti-Zika IgM can usually be detected after about 4 days of symptoms, and remains detectable for about 3 months.

Most who are infected with the Zika virus don’t know they have it. For others, symptoms set in after a few days, tend to be mild, last about a week, and can include fever, rash, joint pain, and conjunctivitis. The virus has, however, been associated in Brazil with Guillain-Barre syndrome and microcephaly, although detection in pregnant women does not necessarily mean the fetus has been harmed.

So far, there have been more than 90 confirmed cases of Zika infection in the United States, most, but not all, in people who had recently traveled to endemic areas.

The FDA did not report sensitivity and specificity figures, but it’s clear from what it did say that reliability is an issue. Closely-related flavivirus infections, such as dengue fever, can trigger false positives, and in patients vaccinated against yellow fever or Japanese encephalitis, cross-reactive antibodies can also “make it difficult to identify which flavivirus is causing the patient’s current illness,” the fact sheet noted.

False negatives should be considered when “recent exposures or clinical presentation are consistent with Zika virus infection and diagnostic tests for other causes of illness are negative. Conversely, a negative result in an asymptomatic patient with a lower likelihood of exposure (e.g., a short term traveler to an affected area) may suggest the patient is not infected,” the FDA noted.

Zika MAC-ELISA labeling, fact sheets for patients, and other materials are available on the FDA’s Emergency Use Authorizations webpage. The CDC has a Zika virus site for health care providers, as well.

[email protected]

Officials at the Centers for Disease Control and Prevention reported that they are aware of at least nine cases of laboratory-confirmed Zika virus infection in pregnant travelers, and that in four of these cases, fetuses were either spontaneously lost or aborted.

Confirmed cases of Zika virus infection were reported among women who had traveled to one or more of the following nine areas with ongoing local transmission of Zika virus: American Samoa, Brazil, El Salvador, Guatemala, Haiti, Honduras, Mexico, Puerto Rico, and Samoa, according to the CDC’s latest Morbidity and Mortality Weekly Report (2016 Feb 26. doi: http://dx.doi.org/10.15585/mmwr.mm6508e1er).

The agency is also investigating reports of 10 other cases of pregnant women with possible Zika virus infection.

Of the nine confirmed cases, six women were infected with Zika virus in their first trimester. In two cases, the pregnancies were terminated and two of the pregnancies resulted in stillbirths. Another woman gave birth to an infant with microcephaly, and one woman is still pregnant and has not experienced any complications so far.

Two of the nine women became infected with Zika virus during their second trimesters, one of whom has delivered a healthy infant and the other of whom is still pregnant with no known complications thus far. The last of the nine women, who became infected during her third trimester, gave birth to a healthy infant with no known complications.

There were no Zika virus–related hospitalizations or deaths among the nine women with Zika virus.

“To better understand the effects of Zika virus infection during pregnancy, CDC has established the U.S. Pregnancy Registry for Zika Virus Infection,” announced Dr. Denise J. Jamieson, colead of the Pregnancy and Birth Defects Team at the CDC. “This registry will provide information about the effects of Zika virus on pregnant women and their children.”

Participation in the registry is voluntary and information will be available on the CDC website soon, Dr. Jamieson added. Until then, the CDC maintains a 24/7 consultation hotline for both pregnant women and health care providers concerned about Zika virus infections, at 1-800-CDC-INFO. Patients and providers can also email [email protected].

Additionally, CDC officials stated that they have received reports of at least 14 instances in which Zika virus may have been transmitted between individuals through sexual contact. Two of these cases are confirmed to have been transmitted to women from men who visited a Zika-endemic area, while another four are “probable cases” of sexual transmission, and another six are under investigation. Two reported cases were excluded after receiving additional information.

“Men who reside in or have traveled to an area of ongoing Zika virus transmission and have a pregnant partner should abstain from sexual activity or consistently and correctly use condoms during sex with their pregnant partner for the duration of the pregnancy,” said the CDC in a statement (MMWR. 2016 Feb 26. doi: http://dx.doi.org/10.15585/mmwr.mm6508e2er).

The World Health Organization also released a new situation report on Zika virus, microcephaly, and Guillain-Barré syndrome, saying that although Zika virus has been spreading to more geographic areas since the beginning of the crisis, cases of microcephaly and neonatal malformations are increasing only in Brazil and French Polynesia.

Additionally, the WHO released interim guidelines on psychosocial support for pregnant women who may be infected with Zika virus and families dealing with an infant born with either microcephaly or another neurologic disorder.

At a press briefing on Feb. 26, CDC Director Dr. Tom Frieden, noted that it has been 6 weeks since the CDC issued its first travel warning regarding Zika virus, and that the agency is “learning more about Zika everyday.” He added that the current state of the Zika virus outbreak is an “unprecedented situation.”

But Dr. Frieden also stressed that the exact link between Zika virus infection and microcephaly is still unknown, and it is not clear at what stage in the pregnancy Zika virus affects the fetus.

It’s also unknown whether infants born to mothers with Zika virus infection who don’t develop microcephaly will have any other health problems in the future. “Unfortunately, this is something we may not know for many years,” Dr. Frieden said.

[email protected]

Officials at the Centers for Disease Control and Prevention reported that they are aware of at least nine cases of laboratory-confirmed Zika virus infection in pregnant travelers, and that in four of these cases, fetuses were either spontaneously lost or aborted.

Confirmed cases of Zika virus infection were reported among women who had traveled to one or more of the following nine areas with ongoing local transmission of Zika virus: American Samoa, Brazil, El Salvador, Guatemala, Haiti, Honduras, Mexico, Puerto Rico, and Samoa, according to the CDC’s latest Morbidity and Mortality Weekly Report (2016 Feb 26. doi: http://dx.doi.org/10.15585/mmwr.mm6508e1er).

The agency is also investigating reports of 10 other cases of pregnant women with possible Zika virus infection.

Of the nine confirmed cases, six women were infected with Zika virus in their first trimester. In two cases, the pregnancies were terminated and two of the pregnancies resulted in stillbirths. Another woman gave birth to an infant with microcephaly, and one woman is still pregnant and has not experienced any complications so far.

Two of the nine women became infected with Zika virus during their second trimesters, one of whom has delivered a healthy infant and the other of whom is still pregnant with no known complications thus far. The last of the nine women, who became infected during her third trimester, gave birth to a healthy infant with no known complications.

There were no Zika virus–related hospitalizations or deaths among the nine women with Zika virus.

“To better understand the effects of Zika virus infection during pregnancy, CDC has established the U.S. Pregnancy Registry for Zika Virus Infection,” announced Dr. Denise J. Jamieson, colead of the Pregnancy and Birth Defects Team at the CDC. “This registry will provide information about the effects of Zika virus on pregnant women and their children.”

Participation in the registry is voluntary and information will be available on the CDC website soon, Dr. Jamieson added. Until then, the CDC maintains a 24/7 consultation hotline for both pregnant women and health care providers concerned about Zika virus infections, at 1-800-CDC-INFO. Patients and providers can also email [email protected].

Additionally, CDC officials stated that they have received reports of at least 14 instances in which Zika virus may have been transmitted between individuals through sexual contact. Two of these cases are confirmed to have been transmitted to women from men who visited a Zika-endemic area, while another four are “probable cases” of sexual transmission, and another six are under investigation. Two reported cases were excluded after receiving additional information.

“Men who reside in or have traveled to an area of ongoing Zika virus transmission and have a pregnant partner should abstain from sexual activity or consistently and correctly use condoms during sex with their pregnant partner for the duration of the pregnancy,” said the CDC in a statement (MMWR. 2016 Feb 26. doi: http://dx.doi.org/10.15585/mmwr.mm6508e2er).

The World Health Organization also released a new situation report on Zika virus, microcephaly, and Guillain-Barré syndrome, saying that although Zika virus has been spreading to more geographic areas since the beginning of the crisis, cases of microcephaly and neonatal malformations are increasing only in Brazil and French Polynesia.

Additionally, the WHO released interim guidelines on psychosocial support for pregnant women who may be infected with Zika virus and families dealing with an infant born with either microcephaly or another neurologic disorder.

At a press briefing on Feb. 26, CDC Director Dr. Tom Frieden, noted that it has been 6 weeks since the CDC issued its first travel warning regarding Zika virus, and that the agency is “learning more about Zika everyday.” He added that the current state of the Zika virus outbreak is an “unprecedented situation.”

But Dr. Frieden also stressed that the exact link between Zika virus infection and microcephaly is still unknown, and it is not clear at what stage in the pregnancy Zika virus affects the fetus.

It’s also unknown whether infants born to mothers with Zika virus infection who don’t develop microcephaly will have any other health problems in the future. “Unfortunately, this is something we may not know for many years,” Dr. Frieden said.

[email protected]

Officials at the Centers for Disease Control and Prevention reported that they are aware of at least nine cases of laboratory-confirmed Zika virus infection in pregnant travelers, and that in four of these cases, fetuses were either spontaneously lost or aborted.

Confirmed cases of Zika virus infection were reported among women who had traveled to one or more of the following nine areas with ongoing local transmission of Zika virus: American Samoa, Brazil, El Salvador, Guatemala, Haiti, Honduras, Mexico, Puerto Rico, and Samoa, according to the CDC’s latest Morbidity and Mortality Weekly Report (2016 Feb 26. doi: http://dx.doi.org/10.15585/mmwr.mm6508e1er).

The agency is also investigating reports of 10 other cases of pregnant women with possible Zika virus infection.

Of the nine confirmed cases, six women were infected with Zika virus in their first trimester. In two cases, the pregnancies were terminated and two of the pregnancies resulted in stillbirths. Another woman gave birth to an infant with microcephaly, and one woman is still pregnant and has not experienced any complications so far.

Two of the nine women became infected with Zika virus during their second trimesters, one of whom has delivered a healthy infant and the other of whom is still pregnant with no known complications thus far. The last of the nine women, who became infected during her third trimester, gave birth to a healthy infant with no known complications.

There were no Zika virus–related hospitalizations or deaths among the nine women with Zika virus.

“To better understand the effects of Zika virus infection during pregnancy, CDC has established the U.S. Pregnancy Registry for Zika Virus Infection,” announced Dr. Denise J. Jamieson, colead of the Pregnancy and Birth Defects Team at the CDC. “This registry will provide information about the effects of Zika virus on pregnant women and their children.”

Participation in the registry is voluntary and information will be available on the CDC website soon, Dr. Jamieson added. Until then, the CDC maintains a 24/7 consultation hotline for both pregnant women and health care providers concerned about Zika virus infections, at 1-800-CDC-INFO. Patients and providers can also email [email protected].

Additionally, CDC officials stated that they have received reports of at least 14 instances in which Zika virus may have been transmitted between individuals through sexual contact. Two of these cases are confirmed to have been transmitted to women from men who visited a Zika-endemic area, while another four are “probable cases” of sexual transmission, and another six are under investigation. Two reported cases were excluded after receiving additional information.

“Men who reside in or have traveled to an area of ongoing Zika virus transmission and have a pregnant partner should abstain from sexual activity or consistently and correctly use condoms during sex with their pregnant partner for the duration of the pregnancy,” said the CDC in a statement (MMWR. 2016 Feb 26. doi: http://dx.doi.org/10.15585/mmwr.mm6508e2er).

The World Health Organization also released a new situation report on Zika virus, microcephaly, and Guillain-Barré syndrome, saying that although Zika virus has been spreading to more geographic areas since the beginning of the crisis, cases of microcephaly and neonatal malformations are increasing only in Brazil and French Polynesia.

Additionally, the WHO released interim guidelines on psychosocial support for pregnant women who may be infected with Zika virus and families dealing with an infant born with either microcephaly or another neurologic disorder.

At a press briefing on Feb. 26, CDC Director Dr. Tom Frieden, noted that it has been 6 weeks since the CDC issued its first travel warning regarding Zika virus, and that the agency is “learning more about Zika everyday.” He added that the current state of the Zika virus outbreak is an “unprecedented situation.”

But Dr. Frieden also stressed that the exact link between Zika virus infection and microcephaly is still unknown, and it is not clear at what stage in the pregnancy Zika virus affects the fetus.

It’s also unknown whether infants born to mothers with Zika virus infection who don’t develop microcephaly will have any other health problems in the future. “Unfortunately, this is something we may not know for many years,” Dr. Frieden said.

[email protected]

Zika virus infection in pregnant women may be linked to hydrops fetalis and fetal demise, according to a case report published online Feb. 25 in PLOS Neglected Tropical Diseases.

A 20-year-old pregnant woman without history or signs of Zika virus infection was referred to the Hospital Geral Roberto Santos in Salvador, Brazil, in the 18th week of gestation because of low fetal weight, but by week 26 and 30, ultrasound examinations showed microcephaly, hydranencephaly, intracranial calcifications, destructive lesions of posterior fossa, and evidence of hydrothorax, ascites, and subcutaneous edema.

CDC/ Cynthia Goldsmith

Ultrasound examination at week 32 showed fetal demise, and after delivery, researchers found evidence of Zika virus in the brain and in the cerebrospinal and amniotic fluid, but not in the heart, lung, liver, eye, or placenta (PLoS Negl Trop Dis. 2016 Feb 25. doi: 10.1371/journal.pntd.0004517).

“This case report of a fetus provides additional evidence for the link between ZIKV [Zika virus] infection and microcephaly,” wrote Dr. Manoel Sarno of Hospital Geral Roberto Santos, and his coauthors. “Furthermore, it serves as an alert to clinicians that in addition to central nervous system and ophthalmological manifestations, congenital ZIKV infection may cause hydrops fetalis and fetal demise.”

The researchers reported having no financial disclosures.

Zika virus infection in pregnant women may be linked to hydrops fetalis and fetal demise, according to a case report published online Feb. 25 in PLOS Neglected Tropical Diseases.

A 20-year-old pregnant woman without history or signs of Zika virus infection was referred to the Hospital Geral Roberto Santos in Salvador, Brazil, in the 18th week of gestation because of low fetal weight, but by week 26 and 30, ultrasound examinations showed microcephaly, hydranencephaly, intracranial calcifications, destructive lesions of posterior fossa, and evidence of hydrothorax, ascites, and subcutaneous edema.

CDC/ Cynthia Goldsmith

Ultrasound examination at week 32 showed fetal demise, and after delivery, researchers found evidence of Zika virus in the brain and in the cerebrospinal and amniotic fluid, but not in the heart, lung, liver, eye, or placenta (PLoS Negl Trop Dis. 2016 Feb 25. doi: 10.1371/journal.pntd.0004517).

“This case report of a fetus provides additional evidence for the link between ZIKV [Zika virus] infection and microcephaly,” wrote Dr. Manoel Sarno of Hospital Geral Roberto Santos, and his coauthors. “Furthermore, it serves as an alert to clinicians that in addition to central nervous system and ophthalmological manifestations, congenital ZIKV infection may cause hydrops fetalis and fetal demise.”

The researchers reported having no financial disclosures.

Zika virus infection in pregnant women may be linked to hydrops fetalis and fetal demise, according to a case report published online Feb. 25 in PLOS Neglected Tropical Diseases.

A 20-year-old pregnant woman without history or signs of Zika virus infection was referred to the Hospital Geral Roberto Santos in Salvador, Brazil, in the 18th week of gestation because of low fetal weight, but by week 26 and 30, ultrasound examinations showed microcephaly, hydranencephaly, intracranial calcifications, destructive lesions of posterior fossa, and evidence of hydrothorax, ascites, and subcutaneous edema.

CDC/ Cynthia Goldsmith

Ultrasound examination at week 32 showed fetal demise, and after delivery, researchers found evidence of Zika virus in the brain and in the cerebrospinal and amniotic fluid, but not in the heart, lung, liver, eye, or placenta (PLoS Negl Trop Dis. 2016 Feb 25. doi: 10.1371/journal.pntd.0004517).

“This case report of a fetus provides additional evidence for the link between ZIKV [Zika virus] infection and microcephaly,” wrote Dr. Manoel Sarno of Hospital Geral Roberto Santos, and his coauthors. “Furthermore, it serves as an alert to clinicians that in addition to central nervous system and ophthalmological manifestations, congenital ZIKV infection may cause hydrops fetalis and fetal demise.”

The researchers reported having no financial disclosures.

BOSTON – A majority of Ebola virus survivors continue to have significant physical, psychological, and sociological consequences for an extended period after discharge, investigators report.

Among 417 Ebola virus survivors enrolled in a follow-up study in Guinea, about 80% had residual clinical signs up to 9 months after discharge, reported Dr. Eric Delaporte of the French National Institute of Health and Medical Research (INSERM) and Montpellier (France) University.

Results of a second, small study, also from Guinea, suggest that up to 10% of men infected with Ebola have semen that remains positive for the virus for nearly a year after disease onset, said Dr. Daouda Sissoko of INSERM in Bordeaux, France.

“The results describe a post-Ebola syndrome with frequent clinical symptoms long after discharge, the gravity of ocular complications, long-term RNA positivity in semen, and the frequency of psychological consequences of the disease,” Dr. Delaporte said at a media briefing prior to presentation of the data in an oral session at the 2016 Conference on Retroviruses and Opportunistic Infections.

Dr. Delaporte is a coinvestigator in the Postebogui Cohort Study looking at Ebola survivors in Conakry and Macenta, Guinea. The goals of the study are to provide follow-up care for survivors and to describe the clinical, biologic, virologic, immunologic, and psychosocial consequences of infection with Ebola virus.

At CROI 2016, investigators reported on the first 417 patients enrolled, including 60 children. The median age was 28 years.

The investigators found that 46% of patients reported joint pains or other rheumatologic signs, 32% had neuropsychiatric signs, 29% reported chronic headache, 22% reported fatigue, and 16% had ophthalmologic signs,

Ophthalmic slit-lamp examinations in 160 patients showed 24 cases of uveitis, 4 cases of episcleritis, 2 cases of keratitis, and 2 cases of blindness in children due to inflammatory cataracts.

Of 160 semen samples tested, 28% were positive for Ebola RNA up to 9 months after disease onset. By 1 year, however, all semen samples tested negative, Dr. Delaporte said.

The investigators also found that among 131 patients discharged from an Ebola treatment center in the Guinean capital of Conakry and followed for a mean of 5 months, 20% had a score on the Center for Epidemiologic Studies depression scale (CES-D) that indicated the patients could benefit from psychological or psychiatric interventions.

Viral reservoir in semen?

In the second study, Dr. Sissoko and colleagues enrolled 26 men who had been discharged from three Ebola treatment units in coastal regions of Guinea from February through June, 2015. The investigators obtained semen specimens every 3-6 weeks until two consecutive samples were negative for Ebola virus on reverse transcriptase polymerase chain reaction testing (RT-PCR).

In all, 19 of the men had semen positive for Ebola RNA at baseline. At a median of 250 days of follow-up 25% of patients continued to have semen positive for Ebola.

The investigators used linear mixed modeling to estimate that at 11 months, approximately 10% of patients will continue to shed Ebola virus in semen, Dr. Sissoko said.

The investigators recommend testing semen samples from each man who has recovered from an Ebola infection until the semen test negative on two consecutive samples.

Both studies were supported by INSERM. Dr. Delaporte and Dr Sissoko reported having no conflicts of interest.

BOSTON – A majority of Ebola virus survivors continue to have significant physical, psychological, and sociological consequences for an extended period after discharge, investigators report.

Among 417 Ebola virus survivors enrolled in a follow-up study in Guinea, about 80% had residual clinical signs up to 9 months after discharge, reported Dr. Eric Delaporte of the French National Institute of Health and Medical Research (INSERM) and Montpellier (France) University.

Results of a second, small study, also from Guinea, suggest that up to 10% of men infected with Ebola have semen that remains positive for the virus for nearly a year after disease onset, said Dr. Daouda Sissoko of INSERM in Bordeaux, France.

“The results describe a post-Ebola syndrome with frequent clinical symptoms long after discharge, the gravity of ocular complications, long-term RNA positivity in semen, and the frequency of psychological consequences of the disease,” Dr. Delaporte said at a media briefing prior to presentation of the data in an oral session at the 2016 Conference on Retroviruses and Opportunistic Infections.

Dr. Delaporte is a coinvestigator in the Postebogui Cohort Study looking at Ebola survivors in Conakry and Macenta, Guinea. The goals of the study are to provide follow-up care for survivors and to describe the clinical, biologic, virologic, immunologic, and psychosocial consequences of infection with Ebola virus.

At CROI 2016, investigators reported on the first 417 patients enrolled, including 60 children. The median age was 28 years.

The investigators found that 46% of patients reported joint pains or other rheumatologic signs, 32% had neuropsychiatric signs, 29% reported chronic headache, 22% reported fatigue, and 16% had ophthalmologic signs,

Ophthalmic slit-lamp examinations in 160 patients showed 24 cases of uveitis, 4 cases of episcleritis, 2 cases of keratitis, and 2 cases of blindness in children due to inflammatory cataracts.

Of 160 semen samples tested, 28% were positive for Ebola RNA up to 9 months after disease onset. By 1 year, however, all semen samples tested negative, Dr. Delaporte said.

The investigators also found that among 131 patients discharged from an Ebola treatment center in the Guinean capital of Conakry and followed for a mean of 5 months, 20% had a score on the Center for Epidemiologic Studies depression scale (CES-D) that indicated the patients could benefit from psychological or psychiatric interventions.

Viral reservoir in semen?

In the second study, Dr. Sissoko and colleagues enrolled 26 men who had been discharged from three Ebola treatment units in coastal regions of Guinea from February through June, 2015. The investigators obtained semen specimens every 3-6 weeks until two consecutive samples were negative for Ebola virus on reverse transcriptase polymerase chain reaction testing (RT-PCR).

In all, 19 of the men had semen positive for Ebola RNA at baseline. At a median of 250 days of follow-up 25% of patients continued to have semen positive for Ebola.

The investigators used linear mixed modeling to estimate that at 11 months, approximately 10% of patients will continue to shed Ebola virus in semen, Dr. Sissoko said.

The investigators recommend testing semen samples from each man who has recovered from an Ebola infection until the semen test negative on two consecutive samples.

Both studies were supported by INSERM. Dr. Delaporte and Dr Sissoko reported having no conflicts of interest.

BOSTON – A majority of Ebola virus survivors continue to have significant physical, psychological, and sociological consequences for an extended period after discharge, investigators report.

Among 417 Ebola virus survivors enrolled in a follow-up study in Guinea, about 80% had residual clinical signs up to 9 months after discharge, reported Dr. Eric Delaporte of the French National Institute of Health and Medical Research (INSERM) and Montpellier (France) University.

Results of a second, small study, also from Guinea, suggest that up to 10% of men infected with Ebola have semen that remains positive for the virus for nearly a year after disease onset, said Dr. Daouda Sissoko of INSERM in Bordeaux, France.

“The results describe a post-Ebola syndrome with frequent clinical symptoms long after discharge, the gravity of ocular complications, long-term RNA positivity in semen, and the frequency of psychological consequences of the disease,” Dr. Delaporte said at a media briefing prior to presentation of the data in an oral session at the 2016 Conference on Retroviruses and Opportunistic Infections.

Dr. Delaporte is a coinvestigator in the Postebogui Cohort Study looking at Ebola survivors in Conakry and Macenta, Guinea. The goals of the study are to provide follow-up care for survivors and to describe the clinical, biologic, virologic, immunologic, and psychosocial consequences of infection with Ebola virus.

At CROI 2016, investigators reported on the first 417 patients enrolled, including 60 children. The median age was 28 years.

The investigators found that 46% of patients reported joint pains or other rheumatologic signs, 32% had neuropsychiatric signs, 29% reported chronic headache, 22% reported fatigue, and 16% had ophthalmologic signs,

Ophthalmic slit-lamp examinations in 160 patients showed 24 cases of uveitis, 4 cases of episcleritis, 2 cases of keratitis, and 2 cases of blindness in children due to inflammatory cataracts.

Of 160 semen samples tested, 28% were positive for Ebola RNA up to 9 months after disease onset. By 1 year, however, all semen samples tested negative, Dr. Delaporte said.

The investigators also found that among 131 patients discharged from an Ebola treatment center in the Guinean capital of Conakry and followed for a mean of 5 months, 20% had a score on the Center for Epidemiologic Studies depression scale (CES-D) that indicated the patients could benefit from psychological or psychiatric interventions.

Viral reservoir in semen?

In the second study, Dr. Sissoko and colleagues enrolled 26 men who had been discharged from three Ebola treatment units in coastal regions of Guinea from February through June, 2015. The investigators obtained semen specimens every 3-6 weeks until two consecutive samples were negative for Ebola virus on reverse transcriptase polymerase chain reaction testing (RT-PCR).

In all, 19 of the men had semen positive for Ebola RNA at baseline. At a median of 250 days of follow-up 25% of patients continued to have semen positive for Ebola.

The investigators used linear mixed modeling to estimate that at 11 months, approximately 10% of patients will continue to shed Ebola virus in semen, Dr. Sissoko said.

The investigators recommend testing semen samples from each man who has recovered from an Ebola infection until the semen test negative on two consecutive samples.

Both studies were supported by INSERM. Dr. Delaporte and Dr Sissoko reported having no conflicts of interest.

Fourteen new reports of possible sexual transmission of Zika virus are being investigated by health officials in the United States, including several that involve pregnant women.

According to a media statement released by the Centers for Disease Control and Prevention on Feb. 23, in 2 of the 14 suspected cases, Zika virus infection “has been confirmed in women whose only known risk factor was sexual contact with an ill male partner who had recently traveled to an area with local Zika virus transmission; testing for the male partners is still pending.”

Confirmatory tests are pending for four additional suspected sexual transmission events, and the investigation is ongoing for an additional eight suspected cases.

“Like previously reported cases of sexual transmission, these cases involve possible transmission of the virus from men to their sex partners,” the statement reads. “At this time, there is no evidence that women can transmit Zika virus to their sex partners; however, more research is needed to understand this issue.”

In a separate announcement on Feb. 23, the CDC added Trinidad and Tobago and the Marshall Islands to the Zika virus travel notices. A full list of affected countries regions can be found at http://wwwnc.cdc.gov/travel/page/zika-information.

[email protected]

Fourteen new reports of possible sexual transmission of Zika virus are being investigated by health officials in the United States, including several that involve pregnant women.

According to a media statement released by the Centers for Disease Control and Prevention on Feb. 23, in 2 of the 14 suspected cases, Zika virus infection “has been confirmed in women whose only known risk factor was sexual contact with an ill male partner who had recently traveled to an area with local Zika virus transmission; testing for the male partners is still pending.”

Confirmatory tests are pending for four additional suspected sexual transmission events, and the investigation is ongoing for an additional eight suspected cases.

“Like previously reported cases of sexual transmission, these cases involve possible transmission of the virus from men to their sex partners,” the statement reads. “At this time, there is no evidence that women can transmit Zika virus to their sex partners; however, more research is needed to understand this issue.”

In a separate announcement on Feb. 23, the CDC added Trinidad and Tobago and the Marshall Islands to the Zika virus travel notices. A full list of affected countries regions can be found at http://wwwnc.cdc.gov/travel/page/zika-information.

[email protected]

Fourteen new reports of possible sexual transmission of Zika virus are being investigated by health officials in the United States, including several that involve pregnant women.

According to a media statement released by the Centers for Disease Control and Prevention on Feb. 23, in 2 of the 14 suspected cases, Zika virus infection “has been confirmed in women whose only known risk factor was sexual contact with an ill male partner who had recently traveled to an area with local Zika virus transmission; testing for the male partners is still pending.”

Confirmatory tests are pending for four additional suspected sexual transmission events, and the investigation is ongoing for an additional eight suspected cases.

“Like previously reported cases of sexual transmission, these cases involve possible transmission of the virus from men to their sex partners,” the statement reads. “At this time, there is no evidence that women can transmit Zika virus to their sex partners; however, more research is needed to understand this issue.”

In a separate announcement on Feb. 23, the CDC added Trinidad and Tobago and the Marshall Islands to the Zika virus travel notices. A full list of affected countries regions can be found at http://wwwnc.cdc.gov/travel/page/zika-information.

[email protected]

Much has rightly been written about the Zika virus in the last few months, yet still we see a number of misunderstandings, rumors, and fears about potential risk, being propagated widely through the media.

Each day brings new developments and expert opinion on the subject, but also, more speculation and subterfuge, with prophylactic advice varying from travel bans, mosquito repellents, contraception, and even abstention from pregnancy.

A crucial factor amplifying this trend, and perhaps the elephant in the room, is the impending 2016 Rio Summer Olympic games. With the world’s eye soon to be focused on Brazil, there is clearly a demand from governments, companies, and other interested parties to ensure they safeguard their respective populations as best they can. Unfortunately, this also means we have seen a number of them act too hastily in their assessment of the risks presented by the Zika virus.

So, what are the risks? Well, we know for sure that there is no vaccine, and it is unlikely we will see one developed this year. But the risk to adults and healthy individuals is still relatively small, as symptoms of Zika virus infection are comparable with the common cold – and certainly not life threatening or even highly infectious in the way prior tropical diseases from Africa, like Ebola, have been. In fact, Zika remained an “unsexy” and largely forgotten virus until we saw the recent probable linkages with microcephaly.

The greatest risk currently recognized is clearly to women who are pregnant or are planning to be pregnant in the near future, and at this point, we believe the risk is probably greatest in the first trimester. This is obviously a major challenge for the domestic populations of Latin America, especially when it is at present unclear whether there is any risk in asymptomatic cases of Zika. From the information we have, and until a fuller understanding of the virus risk is known, it appears that the strongest link of microcephaly presents in cases in which patients have shown symptoms; however, 25% of the mothers of babies with microcephaly remain without any symptoms. And this is, of course, a situation made even more complex by the religious elements of society in South America, where contraception remains enshrouded in cultural stigma and abortion is illegal in many countries – even in those with cases of known prebirth microcephaly.

With no vaccine on the horizon and no cure or effective treatment once infected, clearly, the only viable preventive technique is to cut the spread of the virus. In this case, we must look to reduce the vectors of this disease – namely the Aedes aegypti mosquito. This particular type of Aedes mosquito is prominent throughout tropical regions – namely much of Latin America, South Asia, around the Gulf coast, and in isolated pockets near the Black Sea in Europe. In terms of the virus and the regions in which it has been found, most cases appear in the Latin American mainland, the Caribbean, and Cape Verde – although it may be just a matter of time before it spreads into the Aedes aegypti mosquito’s other habitats within Africa and even Asia. And, of course, it is essential we continue to investigate how viable a vector other species of the Aedes mosquito may be.

Despite these concerns, the risk in terms of the 2016 Olympics, especially for traveling populations, remains low – with the notable exception of pregnant women. In fact, the U.S. Centers for Disease Control and Prevention recommends that any travelers who are pregnant (at any stage/trimester) or planning to become pregnant, should avoid traveling to areas with Zika virus outbreaks. If they cannot avoid travel or if people live in areas where Zika virus transmission is known to occur, meticulous efforts to avoid mosquito bites during both daytime and nighttime hours must be adhered to. While it may sound a rather low-tech solution for modern health care, pregnant women in Zika-affected areas should wear protective clothing, apply a U.S. Environmental Protection Agency–approved insect repellent, and sleep in a screened room or under a mosquito net. However, it is also important to note that the Aedes aegypti mosquitoes predominantly bite during the day, especially around dawn and dusk, and therefore the correct timing and use of mosquito repellents and other personal protection measures are essential.

One final important point to emphasize is that contraception for travelers during the Rio Olympics, and when they return home, is another area of vigilance. By this, we mean both men and women, as evidence suggests Zika may be able to survive in semen for up to 1 month after infection – some reports even suggest cases of Zika remaining in semen for several months. However, the advice remains the same, if you were symptomless, then 1 month of condom use after your return will be enough to mitigate the risk of infection to a sexual partner, and 6 months after return for those who have symptoms.

The obvious unknown is the symptomless cases: Can the virus remain transmissible after the return of an athlete or visitor to the games? This is a crucial point and helps explain where there are still a number of misunderstandings. While in Brazil’s population there are some symptomless cases, people from abroad with no prior exposure to Zika virus (and therefore no resistance), would certainly have some symptoms. This remains true for both North Americans and Europeans, and so they are at no risk of further spreading the virus 1 month after their return from Brazil – should they not present any symptoms.

In one recent case of overkill, Kenya threatened to boycott the Summer Games entirely on safety grounds, a move clearly based on no identifiable scientific evidence, as the risk for athletes alone remains very low and fundamentally manageable. Conversely, the other controversial advice I have recently seen stems from the World Health Organization itself – which suggested women in Latin America should not put off pregnancy for fear of Zika. But until more information is known, and the RNA is properly analyzed or a vaccine becomes available, this is not a position I can yet support. We need to fully understand the risks of Zika virus infection, and there is still a long way to go.

Prof. Dr. Eskild Petersen is a member of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) study group for Infections in Travellers and Migrants (ESGITM) as well as a professor of tropical medicine at Aarhus University Hospital, Denmark, and senior consultant of infectious diseases at the Royal Hospital, Muscat, Oman. He has undertaken work on infectious diseases, clinical immunology, and tropical and travel medicine. His recent research focuses on the rapid spread of Zika virus in the Americas and the implications for the 2016 Rio Olympic Games.

Much has rightly been written about the Zika virus in the last few months, yet still we see a number of misunderstandings, rumors, and fears about potential risk, being propagated widely through the media.

Each day brings new developments and expert opinion on the subject, but also, more speculation and subterfuge, with prophylactic advice varying from travel bans, mosquito repellents, contraception, and even abstention from pregnancy.

A crucial factor amplifying this trend, and perhaps the elephant in the room, is the impending 2016 Rio Summer Olympic games. With the world’s eye soon to be focused on Brazil, there is clearly a demand from governments, companies, and other interested parties to ensure they safeguard their respective populations as best they can. Unfortunately, this also means we have seen a number of them act too hastily in their assessment of the risks presented by the Zika virus.

So, what are the risks? Well, we know for sure that there is no vaccine, and it is unlikely we will see one developed this year. But the risk to adults and healthy individuals is still relatively small, as symptoms of Zika virus infection are comparable with the common cold – and certainly not life threatening or even highly infectious in the way prior tropical diseases from Africa, like Ebola, have been. In fact, Zika remained an “unsexy” and largely forgotten virus until we saw the recent probable linkages with microcephaly.

The greatest risk currently recognized is clearly to women who are pregnant or are planning to be pregnant in the near future, and at this point, we believe the risk is probably greatest in the first trimester. This is obviously a major challenge for the domestic populations of Latin America, especially when it is at present unclear whether there is any risk in asymptomatic cases of Zika. From the information we have, and until a fuller understanding of the virus risk is known, it appears that the strongest link of microcephaly presents in cases in which patients have shown symptoms; however, 25% of the mothers of babies with microcephaly remain without any symptoms. And this is, of course, a situation made even more complex by the religious elements of society in South America, where contraception remains enshrouded in cultural stigma and abortion is illegal in many countries – even in those with cases of known prebirth microcephaly.

With no vaccine on the horizon and no cure or effective treatment once infected, clearly, the only viable preventive technique is to cut the spread of the virus. In this case, we must look to reduce the vectors of this disease – namely the Aedes aegypti mosquito. This particular type of Aedes mosquito is prominent throughout tropical regions – namely much of Latin America, South Asia, around the Gulf coast, and in isolated pockets near the Black Sea in Europe. In terms of the virus and the regions in which it has been found, most cases appear in the Latin American mainland, the Caribbean, and Cape Verde – although it may be just a matter of time before it spreads into the Aedes aegypti mosquito’s other habitats within Africa and even Asia. And, of course, it is essential we continue to investigate how viable a vector other species of the Aedes mosquito may be.

Despite these concerns, the risk in terms of the 2016 Olympics, especially for traveling populations, remains low – with the notable exception of pregnant women. In fact, the U.S. Centers for Disease Control and Prevention recommends that any travelers who are pregnant (at any stage/trimester) or planning to become pregnant, should avoid traveling to areas with Zika virus outbreaks. If they cannot avoid travel or if people live in areas where Zika virus transmission is known to occur, meticulous efforts to avoid mosquito bites during both daytime and nighttime hours must be adhered to. While it may sound a rather low-tech solution for modern health care, pregnant women in Zika-affected areas should wear protective clothing, apply a U.S. Environmental Protection Agency–approved insect repellent, and sleep in a screened room or under a mosquito net. However, it is also important to note that the Aedes aegypti mosquitoes predominantly bite during the day, especially around dawn and dusk, and therefore the correct timing and use of mosquito repellents and other personal protection measures are essential.

One final important point to emphasize is that contraception for travelers during the Rio Olympics, and when they return home, is another area of vigilance. By this, we mean both men and women, as evidence suggests Zika may be able to survive in semen for up to 1 month after infection – some reports even suggest cases of Zika remaining in semen for several months. However, the advice remains the same, if you were symptomless, then 1 month of condom use after your return will be enough to mitigate the risk of infection to a sexual partner, and 6 months after return for those who have symptoms.

The obvious unknown is the symptomless cases: Can the virus remain transmissible after the return of an athlete or visitor to the games? This is a crucial point and helps explain where there are still a number of misunderstandings. While in Brazil’s population there are some symptomless cases, people from abroad with no prior exposure to Zika virus (and therefore no resistance), would certainly have some symptoms. This remains true for both North Americans and Europeans, and so they are at no risk of further spreading the virus 1 month after their return from Brazil – should they not present any symptoms.

In one recent case of overkill, Kenya threatened to boycott the Summer Games entirely on safety grounds, a move clearly based on no identifiable scientific evidence, as the risk for athletes alone remains very low and fundamentally manageable. Conversely, the other controversial advice I have recently seen stems from the World Health Organization itself – which suggested women in Latin America should not put off pregnancy for fear of Zika. But until more information is known, and the RNA is properly analyzed or a vaccine becomes available, this is not a position I can yet support. We need to fully understand the risks of Zika virus infection, and there is still a long way to go.

Prof. Dr. Eskild Petersen is a member of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) study group for Infections in Travellers and Migrants (ESGITM) as well as a professor of tropical medicine at Aarhus University Hospital, Denmark, and senior consultant of infectious diseases at the Royal Hospital, Muscat, Oman. He has undertaken work on infectious diseases, clinical immunology, and tropical and travel medicine. His recent research focuses on the rapid spread of Zika virus in the Americas and the implications for the 2016 Rio Olympic Games.

Much has rightly been written about the Zika virus in the last few months, yet still we see a number of misunderstandings, rumors, and fears about potential risk, being propagated widely through the media.

Each day brings new developments and expert opinion on the subject, but also, more speculation and subterfuge, with prophylactic advice varying from travel bans, mosquito repellents, contraception, and even abstention from pregnancy.

A crucial factor amplifying this trend, and perhaps the elephant in the room, is the impending 2016 Rio Summer Olympic games. With the world’s eye soon to be focused on Brazil, there is clearly a demand from governments, companies, and other interested parties to ensure they safeguard their respective populations as best they can. Unfortunately, this also means we have seen a number of them act too hastily in their assessment of the risks presented by the Zika virus.

So, what are the risks? Well, we know for sure that there is no vaccine, and it is unlikely we will see one developed this year. But the risk to adults and healthy individuals is still relatively small, as symptoms of Zika virus infection are comparable with the common cold – and certainly not life threatening or even highly infectious in the way prior tropical diseases from Africa, like Ebola, have been. In fact, Zika remained an “unsexy” and largely forgotten virus until we saw the recent probable linkages with microcephaly.

The greatest risk currently recognized is clearly to women who are pregnant or are planning to be pregnant in the near future, and at this point, we believe the risk is probably greatest in the first trimester. This is obviously a major challenge for the domestic populations of Latin America, especially when it is at present unclear whether there is any risk in asymptomatic cases of Zika. From the information we have, and until a fuller understanding of the virus risk is known, it appears that the strongest link of microcephaly presents in cases in which patients have shown symptoms; however, 25% of the mothers of babies with microcephaly remain without any symptoms. And this is, of course, a situation made even more complex by the religious elements of society in South America, where contraception remains enshrouded in cultural stigma and abortion is illegal in many countries – even in those with cases of known prebirth microcephaly.

With no vaccine on the horizon and no cure or effective treatment once infected, clearly, the only viable preventive technique is to cut the spread of the virus. In this case, we must look to reduce the vectors of this disease – namely the Aedes aegypti mosquito. This particular type of Aedes mosquito is prominent throughout tropical regions – namely much of Latin America, South Asia, around the Gulf coast, and in isolated pockets near the Black Sea in Europe. In terms of the virus and the regions in which it has been found, most cases appear in the Latin American mainland, the Caribbean, and Cape Verde – although it may be just a matter of time before it spreads into the Aedes aegypti mosquito’s other habitats within Africa and even Asia. And, of course, it is essential we continue to investigate how viable a vector other species of the Aedes mosquito may be.

Despite these concerns, the risk in terms of the 2016 Olympics, especially for traveling populations, remains low – with the notable exception of pregnant women. In fact, the U.S. Centers for Disease Control and Prevention recommends that any travelers who are pregnant (at any stage/trimester) or planning to become pregnant, should avoid traveling to areas with Zika virus outbreaks. If they cannot avoid travel or if people live in areas where Zika virus transmission is known to occur, meticulous efforts to avoid mosquito bites during both daytime and nighttime hours must be adhered to. While it may sound a rather low-tech solution for modern health care, pregnant women in Zika-affected areas should wear protective clothing, apply a U.S. Environmental Protection Agency–approved insect repellent, and sleep in a screened room or under a mosquito net. However, it is also important to note that the Aedes aegypti mosquitoes predominantly bite during the day, especially around dawn and dusk, and therefore the correct timing and use of mosquito repellents and other personal protection measures are essential.

One final important point to emphasize is that contraception for travelers during the Rio Olympics, and when they return home, is another area of vigilance. By this, we mean both men and women, as evidence suggests Zika may be able to survive in semen for up to 1 month after infection – some reports even suggest cases of Zika remaining in semen for several months. However, the advice remains the same, if you were symptomless, then 1 month of condom use after your return will be enough to mitigate the risk of infection to a sexual partner, and 6 months after return for those who have symptoms.

The obvious unknown is the symptomless cases: Can the virus remain transmissible after the return of an athlete or visitor to the games? This is a crucial point and helps explain where there are still a number of misunderstandings. While in Brazil’s population there are some symptomless cases, people from abroad with no prior exposure to Zika virus (and therefore no resistance), would certainly have some symptoms. This remains true for both North Americans and Europeans, and so they are at no risk of further spreading the virus 1 month after their return from Brazil – should they not present any symptoms.

In one recent case of overkill, Kenya threatened to boycott the Summer Games entirely on safety grounds, a move clearly based on no identifiable scientific evidence, as the risk for athletes alone remains very low and fundamentally manageable. Conversely, the other controversial advice I have recently seen stems from the World Health Organization itself – which suggested women in Latin America should not put off pregnancy for fear of Zika. But until more information is known, and the RNA is properly analyzed or a vaccine becomes available, this is not a position I can yet support. We need to fully understand the risks of Zika virus infection, and there is still a long way to go.

Prof. Dr. Eskild Petersen is a member of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) study group for Infections in Travellers and Migrants (ESGITM) as well as a professor of tropical medicine at Aarhus University Hospital, Denmark, and senior consultant of infectious diseases at the Royal Hospital, Muscat, Oman. He has undertaken work on infectious diseases, clinical immunology, and tropical and travel medicine. His recent research focuses on the rapid spread of Zika virus in the Americas and the implications for the 2016 Rio Olympic Games.

The Centers for Disease Control and Prevention has updated its interim guidelines on treatment of infants born to mothers who may have been exposed to Zika virus during pregnancy, adding new protocols and expanding the scope of its guidance to include all children under age 18 years.

The updated guidelines, which were released Feb. 19, call for “routine care” for infants whose mothers traveled to or resided in areas with Zika virus transmission during pregnancy but did not receive Zika virus testing, provided that the infant has a normal head circumference, normal prenatal and postnatal ultrasounds, and a normal physical examination (Morb Mortal Wkly Rep. 2016;65[early release]:1-6).

If an infant’s mother has traveled to a Zika-endemic area, the first step is screening the infant for microcephaly or intracranial calcifications, either prenatally or at birth. If such defects are found, a complete physical examination and Zika virus tests should be performed on the infant.

If tests are positive or inconclusive for Zika virus infection, an additional clinical evaluation is warranted, as well as an assessment for possible long-term sequelae.

Even if no microcephaly or intracranial calcification is detected in the infant, the guidelines state that the mother should still undergo testing for Zika virus infection. If test results are negative, then “routine care” of the infant can proceed; however, positive or inconclusive results should be followed by a physical examination of the infant.

For laboratory testing of congenital Zika virus infection, infant serum should be tested for Zika virus RNA, immunoglobulin M (IgM), dengue virus IgM, and related neutralizing antibodies. If testing on a placenta or umbilical cord sample, use Zika virus immunohistochemical staining, while reverse transcription–polymerase chain reaction (RT-PCR) should be used on fixed or frozen tissue.

Acute Zika virus infections should be tested via RT-PCR for Zika virus RNA of either the serum or cerebrospinal fluid in children who have been symptomatic for less than 7 days. If symptoms have been present for 4 or more days, but Zika virus RNA has not been detected, then the serum or cerebrospinal fluid should be tested for Zika virus IgM and dengue virus IgM, along with related neutralizing antibodies.

All children under age 18 years should be considered likely for Zika infection if they have traveled to or resided in a Zika-endemic area within the previous 2 weeks and have at least two of the following known symptoms of Zika virus infection: fever, rash, conjunctivitis, and arthralgia. The same criteria apply to infants during the first 2 weeks of life if the mother has been to an area where Zika is endemic and if the infant exhibits any two symptoms of the virus.

“Arthralgia can be difficult to detect in infants and young children, and can manifest as irritability, walking with a limp (for ambulatory children), difficulty moving or refusing to move an extremity, pain on palpation, or pain with active or passive movement of the affected joint,” according to the guidelines.

NSAIDs should not be used to treat potential Zika virus infections until dengue virus infection has been definitively ruled out as the cause of illness, because of “the potential for hemorrhagic complications of dengue fever.” Further, no child under age 6 months should be prescribed NSAIDs, and no children of any age who present with acute viral illness should be given aspirin, because of associations with Reye syndrome.

Although Zika virus RNA has been isolated in breast milk, there have been no reported cases of the virus being transmitted via breastfeeding. The CDC considers breastfeeding by mothers with Zika virus infections to be safe, saying that “the benefits of breastfeeding outweigh the theoretical risks of Zika virus transmission through breast milk.”

For infants and children, the best way to avoid Zika virus infection is to avoid getting bitten by mosquitoes. The most effective ways to prevent mosquito bites are by “using air conditioning or window and door screens when indoors, wearing long-sleeved shirts and long pants, using permethrin-treated clothing and gear, and using insect repellents.” The CDC also warns against using oil of lemon eucalyptus on children under age 3 years.

“Persons with Zika virus infection should take steps to prevent mosquito bites for at least the first week of illness to decrease the risk for human-to-mosquito-to-human transmission,” the updated guidelines state.

Information on areas where Zika virus is currently prevalent, and what precautions to take when traveling to these areas, can be found on the CDC website.

[email protected]

The Centers for Disease Control and Prevention has updated its interim guidelines on treatment of infants born to mothers who may have been exposed to Zika virus during pregnancy, adding new protocols and expanding the scope of its guidance to include all children under age 18 years.

The updated guidelines, which were released Feb. 19, call for “routine care” for infants whose mothers traveled to or resided in areas with Zika virus transmission during pregnancy but did not receive Zika virus testing, provided that the infant has a normal head circumference, normal prenatal and postnatal ultrasounds, and a normal physical examination (Morb Mortal Wkly Rep. 2016;65[early release]:1-6).

If an infant’s mother has traveled to a Zika-endemic area, the first step is screening the infant for microcephaly or intracranial calcifications, either prenatally or at birth. If such defects are found, a complete physical examination and Zika virus tests should be performed on the infant.

If tests are positive or inconclusive for Zika virus infection, an additional clinical evaluation is warranted, as well as an assessment for possible long-term sequelae.

Even if no microcephaly or intracranial calcification is detected in the infant, the guidelines state that the mother should still undergo testing for Zika virus infection. If test results are negative, then “routine care” of the infant can proceed; however, positive or inconclusive results should be followed by a physical examination of the infant.

For laboratory testing of congenital Zika virus infection, infant serum should be tested for Zika virus RNA, immunoglobulin M (IgM), dengue virus IgM, and related neutralizing antibodies. If testing on a placenta or umbilical cord sample, use Zika virus immunohistochemical staining, while reverse transcription–polymerase chain reaction (RT-PCR) should be used on fixed or frozen tissue.

Acute Zika virus infections should be tested via RT-PCR for Zika virus RNA of either the serum or cerebrospinal fluid in children who have been symptomatic for less than 7 days. If symptoms have been present for 4 or more days, but Zika virus RNA has not been detected, then the serum or cerebrospinal fluid should be tested for Zika virus IgM and dengue virus IgM, along with related neutralizing antibodies.

All children under age 18 years should be considered likely for Zika infection if they have traveled to or resided in a Zika-endemic area within the previous 2 weeks and have at least two of the following known symptoms of Zika virus infection: fever, rash, conjunctivitis, and arthralgia. The same criteria apply to infants during the first 2 weeks of life if the mother has been to an area where Zika is endemic and if the infant exhibits any two symptoms of the virus.

“Arthralgia can be difficult to detect in infants and young children, and can manifest as irritability, walking with a limp (for ambulatory children), difficulty moving or refusing to move an extremity, pain on palpation, or pain with active or passive movement of the affected joint,” according to the guidelines.

NSAIDs should not be used to treat potential Zika virus infections until dengue virus infection has been definitively ruled out as the cause of illness, because of “the potential for hemorrhagic complications of dengue fever.” Further, no child under age 6 months should be prescribed NSAIDs, and no children of any age who present with acute viral illness should be given aspirin, because of associations with Reye syndrome.

Although Zika virus RNA has been isolated in breast milk, there have been no reported cases of the virus being transmitted via breastfeeding. The CDC considers breastfeeding by mothers with Zika virus infections to be safe, saying that “the benefits of breastfeeding outweigh the theoretical risks of Zika virus transmission through breast milk.”

For infants and children, the best way to avoid Zika virus infection is to avoid getting bitten by mosquitoes. The most effective ways to prevent mosquito bites are by “using air conditioning or window and door screens when indoors, wearing long-sleeved shirts and long pants, using permethrin-treated clothing and gear, and using insect repellents.” The CDC also warns against using oil of lemon eucalyptus on children under age 3 years.

“Persons with Zika virus infection should take steps to prevent mosquito bites for at least the first week of illness to decrease the risk for human-to-mosquito-to-human transmission,” the updated guidelines state.

Information on areas where Zika virus is currently prevalent, and what precautions to take when traveling to these areas, can be found on the CDC website.

[email protected]

The Centers for Disease Control and Prevention has updated its interim guidelines on treatment of infants born to mothers who may have been exposed to Zika virus during pregnancy, adding new protocols and expanding the scope of its guidance to include all children under age 18 years.

The updated guidelines, which were released Feb. 19, call for “routine care” for infants whose mothers traveled to or resided in areas with Zika virus transmission during pregnancy but did not receive Zika virus testing, provided that the infant has a normal head circumference, normal prenatal and postnatal ultrasounds, and a normal physical examination (Morb Mortal Wkly Rep. 2016;65[early release]:1-6).

If an infant’s mother has traveled to a Zika-endemic area, the first step is screening the infant for microcephaly or intracranial calcifications, either prenatally or at birth. If such defects are found, a complete physical examination and Zika virus tests should be performed on the infant.

If tests are positive or inconclusive for Zika virus infection, an additional clinical evaluation is warranted, as well as an assessment for possible long-term sequelae.

Even if no microcephaly or intracranial calcification is detected in the infant, the guidelines state that the mother should still undergo testing for Zika virus infection. If test results are negative, then “routine care” of the infant can proceed; however, positive or inconclusive results should be followed by a physical examination of the infant.

For laboratory testing of congenital Zika virus infection, infant serum should be tested for Zika virus RNA, immunoglobulin M (IgM), dengue virus IgM, and related neutralizing antibodies. If testing on a placenta or umbilical cord sample, use Zika virus immunohistochemical staining, while reverse transcription–polymerase chain reaction (RT-PCR) should be used on fixed or frozen tissue.

Acute Zika virus infections should be tested via RT-PCR for Zika virus RNA of either the serum or cerebrospinal fluid in children who have been symptomatic for less than 7 days. If symptoms have been present for 4 or more days, but Zika virus RNA has not been detected, then the serum or cerebrospinal fluid should be tested for Zika virus IgM and dengue virus IgM, along with related neutralizing antibodies.

All children under age 18 years should be considered likely for Zika infection if they have traveled to or resided in a Zika-endemic area within the previous 2 weeks and have at least two of the following known symptoms of Zika virus infection: fever, rash, conjunctivitis, and arthralgia. The same criteria apply to infants during the first 2 weeks of life if the mother has been to an area where Zika is endemic and if the infant exhibits any two symptoms of the virus.

“Arthralgia can be difficult to detect in infants and young children, and can manifest as irritability, walking with a limp (for ambulatory children), difficulty moving or refusing to move an extremity, pain on palpation, or pain with active or passive movement of the affected joint,” according to the guidelines.

NSAIDs should not be used to treat potential Zika virus infections until dengue virus infection has been definitively ruled out as the cause of illness, because of “the potential for hemorrhagic complications of dengue fever.” Further, no child under age 6 months should be prescribed NSAIDs, and no children of any age who present with acute viral illness should be given aspirin, because of associations with Reye syndrome.

Although Zika virus RNA has been isolated in breast milk, there have been no reported cases of the virus being transmitted via breastfeeding. The CDC considers breastfeeding by mothers with Zika virus infections to be safe, saying that “the benefits of breastfeeding outweigh the theoretical risks of Zika virus transmission through breast milk.”

For infants and children, the best way to avoid Zika virus infection is to avoid getting bitten by mosquitoes. The most effective ways to prevent mosquito bites are by “using air conditioning or window and door screens when indoors, wearing long-sleeved shirts and long pants, using permethrin-treated clothing and gear, and using insect repellents.” The CDC also warns against using oil of lemon eucalyptus on children under age 3 years.

“Persons with Zika virus infection should take steps to prevent mosquito bites for at least the first week of illness to decrease the risk for human-to-mosquito-to-human transmission,” the updated guidelines state.

Information on areas where Zika virus is currently prevalent, and what precautions to take when traveling to these areas, can be found on the CDC website.

[email protected]

WASHINGTON – Once again, the United States is ill-prepared to handle the threat of a global pandemic entering its borders and must commit resources to the development of a Zika virus vaccine, said Dr. Victor J. Dzau, president of the National Academy of Medicine.

Dr. Dzau issued this call to action on Feb. 16 at a workshop centered around the recent Zika virus outbreak and how to combat it. The workshop was convened at the request of the Health and Human Services department.

Deepak Chitnis/Frontline Medical News

Calling Zika virus “a new threat to global health,” Dr. Dzau said the best course of action is for the U.S. and health authorities around the world is to create a “global health risk framework” that would actively work to identify new and emerging public health threats and prevent them from becoming outbreaks. This framework would consist of a global architecture to reduce risk and mitigate the next global health crisis, identification of key resources and applications before an outbreak occurs, successful containment of future outbreaks, and coordinated responses “informed by good planning and evidence, not fear or politics,” he said.

“Global leaders need to step up,” said Dr. Dzau. “They need to step up investments to improve their response and also their preparedness for pandemics and infectious outbreaks.”

One of the most serious concerns about Zika virus has been its effects on pregnant women, as infected mothers have been bearing children with microcephaly in Central and South America. Dr. Laura E. Riley of Massachusetts General Hospital spoke about the gaps in what ob.gyns. currently know about the virus and the best way to treat pregnant women who may have been exposed.

Testing for Zika immunoglobulin M (IgM) antibodies is the “first step” in treating any pregnant woman who has traveled and may have been exposed to the virus, she said. However, Dr. Riley noted that the test is relatively new and “we’re putting a lot of stock into this test that we don’t have a lot of information about.”

Citing a Morbidity and Mortality Weekly Report released by the Centers for Disease Control and Prevention in February, Dr. Riley said that evidence of the link between Zika virus infections and microcephaly is stronger than ever, but there is still doubt as to exactly how microcephaly is caused, and at what point during the pregnancy symptoms begin to present in the fetus.

Serial ultrasounds have shown the slowing of fetal development over the course of a pregnancy – specifically in two Brazilian women examined for the report – but data is still sparse. “The causal relationship between Zika virus and other adverse pregnancy outcomes” is also of critical importance, said Dr. Riley. “I think we have pretty well established the association with microcephaly [but] there may be other neurologic abnormalities that we should be aware of and looking for.”

These other conditions include lissencephaly and intracranial calcification, Dr. Riley said.

“We don’t know what the infection rate is, but more importantly, the incidence of internal fetal transmission by trimester is particularly important as well, and what are the factors that influence that transmission?” asked Dr. Riley. “Is it the severity of internal infection? Is it the maternal immune response? We don’t know. We have information that we can glean from other infections.”

For now, said Dr. Riley is relying largely on the CDC guidance in advising patients.

“I’m taking the CDC guidance and I’m taking my own knowledge of [cytomegalovirus] and rubella and I’m trying to put it all together for Zika virus, for which I know very little,” she said.

Dr. Dzau and Dr. Riley did not report having any relevant financial disclosures.

[email protected]

WASHINGTON – Once again, the United States is ill-prepared to handle the threat of a global pandemic entering its borders and must commit resources to the development of a Zika virus vaccine, said Dr. Victor J. Dzau, president of the National Academy of Medicine.

Dr. Dzau issued this call to action on Feb. 16 at a workshop centered around the recent Zika virus outbreak and how to combat it. The workshop was convened at the request of the Health and Human Services department.

Deepak Chitnis/Frontline Medical News

Calling Zika virus “a new threat to global health,” Dr. Dzau said the best course of action is for the U.S. and health authorities around the world is to create a “global health risk framework” that would actively work to identify new and emerging public health threats and prevent them from becoming outbreaks. This framework would consist of a global architecture to reduce risk and mitigate the next global health crisis, identification of key resources and applications before an outbreak occurs, successful containment of future outbreaks, and coordinated responses “informed by good planning and evidence, not fear or politics,” he said.

“Global leaders need to step up,” said Dr. Dzau. “They need to step up investments to improve their response and also their preparedness for pandemics and infectious outbreaks.”

One of the most serious concerns about Zika virus has been its effects on pregnant women, as infected mothers have been bearing children with microcephaly in Central and South America. Dr. Laura E. Riley of Massachusetts General Hospital spoke about the gaps in what ob.gyns. currently know about the virus and the best way to treat pregnant women who may have been exposed.

Testing for Zika immunoglobulin M (IgM) antibodies is the “first step” in treating any pregnant woman who has traveled and may have been exposed to the virus, she said. However, Dr. Riley noted that the test is relatively new and “we’re putting a lot of stock into this test that we don’t have a lot of information about.”

Citing a Morbidity and Mortality Weekly Report released by the Centers for Disease Control and Prevention in February, Dr. Riley said that evidence of the link between Zika virus infections and microcephaly is stronger than ever, but there is still doubt as to exactly how microcephaly is caused, and at what point during the pregnancy symptoms begin to present in the fetus.

Serial ultrasounds have shown the slowing of fetal development over the course of a pregnancy – specifically in two Brazilian women examined for the report – but data is still sparse. “The causal relationship between Zika virus and other adverse pregnancy outcomes” is also of critical importance, said Dr. Riley. “I think we have pretty well established the association with microcephaly [but] there may be other neurologic abnormalities that we should be aware of and looking for.”

These other conditions include lissencephaly and intracranial calcification, Dr. Riley said.

“We don’t know what the infection rate is, but more importantly, the incidence of internal fetal transmission by trimester is particularly important as well, and what are the factors that influence that transmission?” asked Dr. Riley. “Is it the severity of internal infection? Is it the maternal immune response? We don’t know. We have information that we can glean from other infections.”

For now, said Dr. Riley is relying largely on the CDC guidance in advising patients.

“I’m taking the CDC guidance and I’m taking my own knowledge of [cytomegalovirus] and rubella and I’m trying to put it all together for Zika virus, for which I know very little,” she said.

Dr. Dzau and Dr. Riley did not report having any relevant financial disclosures.

[email protected]

WASHINGTON – Once again, the United States is ill-prepared to handle the threat of a global pandemic entering its borders and must commit resources to the development of a Zika virus vaccine, said Dr. Victor J. Dzau, president of the National Academy of Medicine.

Dr. Dzau issued this call to action on Feb. 16 at a workshop centered around the recent Zika virus outbreak and how to combat it. The workshop was convened at the request of the Health and Human Services department.

Deepak Chitnis/Frontline Medical News

Calling Zika virus “a new threat to global health,” Dr. Dzau said the best course of action is for the U.S. and health authorities around the world is to create a “global health risk framework” that would actively work to identify new and emerging public health threats and prevent them from becoming outbreaks. This framework would consist of a global architecture to reduce risk and mitigate the next global health crisis, identification of key resources and applications before an outbreak occurs, successful containment of future outbreaks, and coordinated responses “informed by good planning and evidence, not fear or politics,” he said.

“Global leaders need to step up,” said Dr. Dzau. “They need to step up investments to improve their response and also their preparedness for pandemics and infectious outbreaks.”

One of the most serious concerns about Zika virus has been its effects on pregnant women, as infected mothers have been bearing children with microcephaly in Central and South America. Dr. Laura E. Riley of Massachusetts General Hospital spoke about the gaps in what ob.gyns. currently know about the virus and the best way to treat pregnant women who may have been exposed.

Testing for Zika immunoglobulin M (IgM) antibodies is the “first step” in treating any pregnant woman who has traveled and may have been exposed to the virus, she said. However, Dr. Riley noted that the test is relatively new and “we’re putting a lot of stock into this test that we don’t have a lot of information about.”

Citing a Morbidity and Mortality Weekly Report released by the Centers for Disease Control and Prevention in February, Dr. Riley said that evidence of the link between Zika virus infections and microcephaly is stronger than ever, but there is still doubt as to exactly how microcephaly is caused, and at what point during the pregnancy symptoms begin to present in the fetus.

Serial ultrasounds have shown the slowing of fetal development over the course of a pregnancy – specifically in two Brazilian women examined for the report – but data is still sparse. “The causal relationship between Zika virus and other adverse pregnancy outcomes” is also of critical importance, said Dr. Riley. “I think we have pretty well established the association with microcephaly [but] there may be other neurologic abnormalities that we should be aware of and looking for.”

These other conditions include lissencephaly and intracranial calcification, Dr. Riley said.

“We don’t know what the infection rate is, but more importantly, the incidence of internal fetal transmission by trimester is particularly important as well, and what are the factors that influence that transmission?” asked Dr. Riley. “Is it the severity of internal infection? Is it the maternal immune response? We don’t know. We have information that we can glean from other infections.”

For now, said Dr. Riley is relying largely on the CDC guidance in advising patients.

“I’m taking the CDC guidance and I’m taking my own knowledge of [cytomegalovirus] and rubella and I’m trying to put it all together for Zika virus, for which I know very little,” she said.

Dr. Dzau and Dr. Riley did not report having any relevant financial disclosures.

[email protected]

Approximately one-third of chikungunya patients who acquired the disease during Caribbean travel reported postchikungunya muscle pain, joint pain, and joint swelling, according to data for 28 patients seen at a single center in 2014. The findings were published in Travel Medicine and Infectious Disease (2016. doi: 10.1016/j.tmaid.2016.01.009).

The researchers contacted 19 of the patients approximately 13 months after their original diagnoses. Of these, 37% described ongoing rheumatic problems; 32% reported joint pain, 32% reported joint swelling, and 26% reported muscle pain.

CDC/Cynthia Goldsmith

Dr. Cosmina Zeana of Bronx-Lebanon Hospital Center, New York, and colleagues initially identified 28 adult patients with a median age of 52 years. Most were Hispanic (96%) and half were women (54%). The average length of stay in the Caribbean was 30 days, and 82% had visited the Dominican Republic. The follow-up data were collected via a telephone questionnaire.

Chikungunya has become endemic in Latin America, the researchers noted. “Of increasing concern is the occurrence of persistent rheumatic and general disabling symptoms that can last for several years following acute infection,” they wrote. Transmission of chikungunya has been documented throughout the Caribbean, but this study is the first known assessment of postchikungunya rheumatologic disorders among individuals diagnosed with acute chikungunya after traveling to the Caribbean in particular, they added.

At follow-up, three patients without preexisting rheumatic disease met criteria for diffuse postchikungunya (pCHIK) musculoskeletal disorders. In addition, four patients with preexisting rheumatic disease reported an increase in symptom severity including worsening knee osteoarthritis in both knees (one patient) and increased joint involvement (three patients).

Significantly more patients with preexisting disease reported using pain medication, compared with those without preexisting disease. However, no significant differences appeared in the percentage of patients in each group reporting other symptoms including joint pain, muscle pain, and joint swelling.

Nearly all the patients presented for acute care with fever (99%), joint pain (89%), myalgia (70%), and joint swelling (68%). The median pain level was 8 on a scale of 1-10.

Other symptoms reported at the time of acute diagnosis included gastrointestinal problems (59%), headache (48%), and rash (48%). Almost half the patients (46%) required inpatient care, with complications including hypotensive episodes, syncope, electrolyte imbalance, and thrombocytopenia.

“Patients seeking pretravel health care in preparation for a trip to the Caribbean – as to any other CHIK-endemic 185 region – need to be comprehensively counseled about the health risks related to the acute stage of the infection as well as related to the risk for developing a potentially long-lasting rheumatic disorder,” the researchers said.

“An integrated care plan for patients with acute CHIK consisting of follow-up appointments with the primary care provider and a rheumatologist with the aim of reducing the time to identify patients with pCHIK rheumatic disorders and initiation of optimal disease management may be useful and need further study,” they added.

The findings were limited by several factors including small sample size, use of self-reports, and narrow geographic range. The researchers had no financial conflicts to disclose.

Approximately one-third of chikungunya patients who acquired the disease during Caribbean travel reported postchikungunya muscle pain, joint pain, and joint swelling, according to data for 28 patients seen at a single center in 2014. The findings were published in Travel Medicine and Infectious Disease (2016. doi: 10.1016/j.tmaid.2016.01.009).

The researchers contacted 19 of the patients approximately 13 months after their original diagnoses. Of these, 37% described ongoing rheumatic problems; 32% reported joint pain, 32% reported joint swelling, and 26% reported muscle pain.

CDC/Cynthia Goldsmith

Dr. Cosmina Zeana of Bronx-Lebanon Hospital Center, New York, and colleagues initially identified 28 adult patients with a median age of 52 years. Most were Hispanic (96%) and half were women (54%). The average length of stay in the Caribbean was 30 days, and 82% had visited the Dominican Republic. The follow-up data were collected via a telephone questionnaire.

Chikungunya has become endemic in Latin America, the researchers noted. “Of increasing concern is the occurrence of persistent rheumatic and general disabling symptoms that can last for several years following acute infection,” they wrote. Transmission of chikungunya has been documented throughout the Caribbean, but this study is the first known assessment of postchikungunya rheumatologic disorders among individuals diagnosed with acute chikungunya after traveling to the Caribbean in particular, they added.

At follow-up, three patients without preexisting rheumatic disease met criteria for diffuse postchikungunya (pCHIK) musculoskeletal disorders. In addition, four patients with preexisting rheumatic disease reported an increase in symptom severity including worsening knee osteoarthritis in both knees (one patient) and increased joint involvement (three patients).

Significantly more patients with preexisting disease reported using pain medication, compared with those without preexisting disease. However, no significant differences appeared in the percentage of patients in each group reporting other symptoms including joint pain, muscle pain, and joint swelling.

Nearly all the patients presented for acute care with fever (99%), joint pain (89%), myalgia (70%), and joint swelling (68%). The median pain level was 8 on a scale of 1-10.

Other symptoms reported at the time of acute diagnosis included gastrointestinal problems (59%), headache (48%), and rash (48%). Almost half the patients (46%) required inpatient care, with complications including hypotensive episodes, syncope, electrolyte imbalance, and thrombocytopenia.

“Patients seeking pretravel health care in preparation for a trip to the Caribbean – as to any other CHIK-endemic 185 region – need to be comprehensively counseled about the health risks related to the acute stage of the infection as well as related to the risk for developing a potentially long-lasting rheumatic disorder,” the researchers said.

“An integrated care plan for patients with acute CHIK consisting of follow-up appointments with the primary care provider and a rheumatologist with the aim of reducing the time to identify patients with pCHIK rheumatic disorders and initiation of optimal disease management may be useful and need further study,” they added.

The findings were limited by several factors including small sample size, use of self-reports, and narrow geographic range. The researchers had no financial conflicts to disclose.

Approximately one-third of chikungunya patients who acquired the disease during Caribbean travel reported postchikungunya muscle pain, joint pain, and joint swelling, according to data for 28 patients seen at a single center in 2014. The findings were published in Travel Medicine and Infectious Disease (2016. doi: 10.1016/j.tmaid.2016.01.009).

The researchers contacted 19 of the patients approximately 13 months after their original diagnoses. Of these, 37% described ongoing rheumatic problems; 32% reported joint pain, 32% reported joint swelling, and 26% reported muscle pain.

CDC/Cynthia Goldsmith

Dr. Cosmina Zeana of Bronx-Lebanon Hospital Center, New York, and colleagues initially identified 28 adult patients with a median age of 52 years. Most were Hispanic (96%) and half were women (54%). The average length of stay in the Caribbean was 30 days, and 82% had visited the Dominican Republic. The follow-up data were collected via a telephone questionnaire.

Chikungunya has become endemic in Latin America, the researchers noted. “Of increasing concern is the occurrence of persistent rheumatic and general disabling symptoms that can last for several years following acute infection,” they wrote. Transmission of chikungunya has been documented throughout the Caribbean, but this study is the first known assessment of postchikungunya rheumatologic disorders among individuals diagnosed with acute chikungunya after traveling to the Caribbean in particular, they added.

At follow-up, three patients without preexisting rheumatic disease met criteria for diffuse postchikungunya (pCHIK) musculoskeletal disorders. In addition, four patients with preexisting rheumatic disease reported an increase in symptom severity including worsening knee osteoarthritis in both knees (one patient) and increased joint involvement (three patients).

Significantly more patients with preexisting disease reported using pain medication, compared with those without preexisting disease. However, no significant differences appeared in the percentage of patients in each group reporting other symptoms including joint pain, muscle pain, and joint swelling.

Nearly all the patients presented for acute care with fever (99%), joint pain (89%), myalgia (70%), and joint swelling (68%). The median pain level was 8 on a scale of 1-10.

Other symptoms reported at the time of acute diagnosis included gastrointestinal problems (59%), headache (48%), and rash (48%). Almost half the patients (46%) required inpatient care, with complications including hypotensive episodes, syncope, electrolyte imbalance, and thrombocytopenia.

“Patients seeking pretravel health care in preparation for a trip to the Caribbean – as to any other CHIK-endemic 185 region – need to be comprehensively counseled about the health risks related to the acute stage of the infection as well as related to the risk for developing a potentially long-lasting rheumatic disorder,” the researchers said.

“An integrated care plan for patients with acute CHIK consisting of follow-up appointments with the primary care provider and a rheumatologist with the aim of reducing the time to identify patients with pCHIK rheumatic disorders and initiation of optimal disease management may be useful and need further study,” they added.

The findings were limited by several factors including small sample size, use of self-reports, and narrow geographic range. The researchers had no financial conflicts to disclose.

A case study conducted in Brazil revealed the presence of Zika virus in the amniotic fluid of two pregnant women, suggesting that the virus can cross the placental barrier and potentially infect the developing fetus.

Both women in the study had their amniotic fluid samples taken at 28 weeks, and later gave birth to babies with microcephaly.

The finding, published online Feb 17 in The Lancet Infectious Diseases (Lancet Infect Dis. 2016 Feb 17. doi: 10.1016/S1473-3099[16]00095-5), does not prove that Zika virus infection causes microcephaly but does suggest the biological plausibility of such a link.

In the same study, the researchers, led by Dr. Ana de Filippis of Oswaldo Cruz Institute in Rio de Janeiro, applied reverse transcription polymerase chain reaction and viral metagenomic sequencing to the viral samples, allowing them to establish that the virus was very closely related to the Zika virus that caused an outbreak in French Polynesia in 2013, and was not a recombinant strain.

©Oswaldo Cruz Institute

The women in the study, age 27 and 35, were from the Brazilian state of Paraíba. Neither woman reported smoking, using recreational drugs or alcohol, or taking medications known to affect fetal development.

Zika virus was not found in the blood or urine of either woman when the amniotic samples were taken, though both had reported earlier symptoms consistent with Zika infection. Other infections, including HIV, dengue, chikungunya, rubella, and herpes viruses, were ruled out.

The results provide important insight into the origin of the Zika virus circulating in Brazil, the researchers wrote in their analysis. Moreover, “our group is the first, to our knowledge, to isolate the whole genome of Zika virus directly from the amniotic fluid of a pregnant woman before delivery, supporting the hypothesis that Zika virus infection could occur through transplacental transmission,” wrote Dr. de Filippis and her colleagues.

Still, little is known about the effects of Zika on the developing central nervous system, the researchers wrote. A connection between Zika virus infections and poor CNS outcomes “remains presumptive, and is based on a temporal association. New studies should be done to investigate whether the Zika virus can infect either neurological precursor cells or final differentiated cells.”

The researchers cautioned that congenital microcephaly has been associated with genetic disorders, chemical exposures, brain injury and uterine infections. Other possible contributors to the current high rate of microcephaly in Brazil, which last year was 20 times higher than in previous years, need to be investigated, they wrote.

Agencies within Brazil’s national government and the city of Rio de Janeiro funded the study, and investigators disclosed no conflicts of interest.

A case study conducted in Brazil revealed the presence of Zika virus in the amniotic fluid of two pregnant women, suggesting that the virus can cross the placental barrier and potentially infect the developing fetus.

Both women in the study had their amniotic fluid samples taken at 28 weeks, and later gave birth to babies with microcephaly.

The finding, published online Feb 17 in The Lancet Infectious Diseases (Lancet Infect Dis. 2016 Feb 17. doi: 10.1016/S1473-3099[16]00095-5), does not prove that Zika virus infection causes microcephaly but does suggest the biological plausibility of such a link.

In the same study, the researchers, led by Dr. Ana de Filippis of Oswaldo Cruz Institute in Rio de Janeiro, applied reverse transcription polymerase chain reaction and viral metagenomic sequencing to the viral samples, allowing them to establish that the virus was very closely related to the Zika virus that caused an outbreak in French Polynesia in 2013, and was not a recombinant strain.

©Oswaldo Cruz Institute

The women in the study, age 27 and 35, were from the Brazilian state of Paraíba. Neither woman reported smoking, using recreational drugs or alcohol, or taking medications known to affect fetal development.

Zika virus was not found in the blood or urine of either woman when the amniotic samples were taken, though both had reported earlier symptoms consistent with Zika infection. Other infections, including HIV, dengue, chikungunya, rubella, and herpes viruses, were ruled out.

The results provide important insight into the origin of the Zika virus circulating in Brazil, the researchers wrote in their analysis. Moreover, “our group is the first, to our knowledge, to isolate the whole genome of Zika virus directly from the amniotic fluid of a pregnant woman before delivery, supporting the hypothesis that Zika virus infection could occur through transplacental transmission,” wrote Dr. de Filippis and her colleagues.

Still, little is known about the effects of Zika on the developing central nervous system, the researchers wrote. A connection between Zika virus infections and poor CNS outcomes “remains presumptive, and is based on a temporal association. New studies should be done to investigate whether the Zika virus can infect either neurological precursor cells or final differentiated cells.”

The researchers cautioned that congenital microcephaly has been associated with genetic disorders, chemical exposures, brain injury and uterine infections. Other possible contributors to the current high rate of microcephaly in Brazil, which last year was 20 times higher than in previous years, need to be investigated, they wrote.

Agencies within Brazil’s national government and the city of Rio de Janeiro funded the study, and investigators disclosed no conflicts of interest.

A case study conducted in Brazil revealed the presence of Zika virus in the amniotic fluid of two pregnant women, suggesting that the virus can cross the placental barrier and potentially infect the developing fetus.

Both women in the study had their amniotic fluid samples taken at 28 weeks, and later gave birth to babies with microcephaly.

The finding, published online Feb 17 in The Lancet Infectious Diseases (Lancet Infect Dis. 2016 Feb 17. doi: 10.1016/S1473-3099[16]00095-5), does not prove that Zika virus infection causes microcephaly but does suggest the biological plausibility of such a link.

In the same study, the researchers, led by Dr. Ana de Filippis of Oswaldo Cruz Institute in Rio de Janeiro, applied reverse transcription polymerase chain reaction and viral metagenomic sequencing to the viral samples, allowing them to establish that the virus was very closely related to the Zika virus that caused an outbreak in French Polynesia in 2013, and was not a recombinant strain.

©Oswaldo Cruz Institute

The women in the study, age 27 and 35, were from the Brazilian state of Paraíba. Neither woman reported smoking, using recreational drugs or alcohol, or taking medications known to affect fetal development.

Zika virus was not found in the blood or urine of either woman when the amniotic samples were taken, though both had reported earlier symptoms consistent with Zika infection. Other infections, including HIV, dengue, chikungunya, rubella, and herpes viruses, were ruled out.

The results provide important insight into the origin of the Zika virus circulating in Brazil, the researchers wrote in their analysis. Moreover, “our group is the first, to our knowledge, to isolate the whole genome of Zika virus directly from the amniotic fluid of a pregnant woman before delivery, supporting the hypothesis that Zika virus infection could occur through transplacental transmission,” wrote Dr. de Filippis and her colleagues.

Still, little is known about the effects of Zika on the developing central nervous system, the researchers wrote. A connection between Zika virus infections and poor CNS outcomes “remains presumptive, and is based on a temporal association. New studies should be done to investigate whether the Zika virus can infect either neurological precursor cells or final differentiated cells.”

The researchers cautioned that congenital microcephaly has been associated with genetic disorders, chemical exposures, brain injury and uterine infections. Other possible contributors to the current high rate of microcephaly in Brazil, which last year was 20 times higher than in previous years, need to be investigated, they wrote.

Agencies within Brazil’s national government and the city of Rio de Janeiro funded the study, and investigators disclosed no conflicts of interest.